November 3, 2026- Abbott announced one-year results for its investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder from the VERITAS study, which show meaningful closure rates of the left atrial appendage and a low incidence of stroke in people with atrial fibrillation (AFib) not caused by a heart valve issue. The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1, 2026, and simultaneously published in JACC: Cardiovascular Interventions. Amulet 360 is Abbott’s next-generation LAA occlusion device designed to reduce the risk of stroke in people with AFib, an irregular heartbeat in the heart’s upper chambers, which is not caused by a heart valve issue (non-valvular) and who may need an alternative to long-term blood-thinning medication.